By Editorial TeamThe pharmaceutical industry, traditionally characterized by lengthy and capital-intensive drug discovery cycles, is undergoing a deep transformation. This shift is largely driven by a strategic pivot towards externalizing foundational AI development, as major players recognize the unparalleled potential of advanced AI models to accelerate the moonshot of automated de novo drug design. This strategic outsourcing represents a collective push, moving beyond incremental improvements to fundamentally reshape how new therapeutics are conceived and brought to market.
The Structural Imperative: Why Pharma Outsources Foundational AI
The complexity and computational demands of developing modern AI foundation models for drug discovery are immense, often exceeding the core competencies and infrastructure of even the largest pharmaceutical companies. This reality has spurred a trend where biopharma giants are forging deep, structural partnerships with AI-native companies and technology leaders. These collaborations are not merely transactional. They are designed to embed advanced AI capabilities directly into the drug discovery pipeline, using specialized expertise in machine learning, high-performance computing, and vast data handling. The goal is to build scalable, generalizable AI frameworks that can tackle diverse biological problems, from target identification to lead optimization, in the end compressing timelines and increasing success rates.
Genentech and NVIDIA: A High-Performance Computing Teamwork
One prominent example of this strategic alignment is the collaboration between Genentech, a pioneering biotechnology company, and NVIDIA, a global leader in accelerated computing and AI. This partnership is proof of the recognition that the sheer computational power required to train and deploy sophisticated AI models for molecular dynamics and protein folding necessitates specialized hardware and software infrastructure. The Genentech-NVIDIA collaboration focuses on using NVIDIA’s AI platforms and expertise to enhance Genentech’s drug discovery and development processes. While specific financial terms are often proprietary, such partnerships typically involve significant investment from the pharmaceutical partner, including access to proprietary biological data and domain expertise, in exchange for modern AI capabilities and computational resources. The structural terms often include multi-year agreements, joint development teams, and performance-based milestones tied to the successful application of AI in specific drug discovery programs. The clinical goals are ambitious, aiming to accelerate the identification of novel drug candidates, optimize their properties, and predict their efficacy and safety earlier in the development cycle. This teamwork positions Genentech to exploit the power of large-scale AI simulations and predictive modeling, areas where NVIDIA’s technology is paramount. Genentech-NVIDIA partnership announcement
Isomorphic Labs and Eli Lilly and Novartis: A DeepMind Pedigree for Drug Discovery
Another key partnership illustrating this trend is the series of discovery deals struck between Isomorphic Labs, an Alphabet company spun out of DeepMind, and pharmaceutical leaders such as Eli Lilly and Novartis. Isomorphic Labs brings to the table a foundational AI approach, rooted in the success of DeepMind’s AlphaFold, which revolutionized protein structure prediction. This expertise is particularly attractive to pharmaceutical companies, which are seeking to use truly novel AI paradigms for therapeutic design. Isomorphic Labs signed multi-target collaborations with pharmaceutical companies, notably Eli Lilly and Novartis, in January 2024. For instance, the deal with Eli Lilly reportedly included an upfront payment of $45 million, with potential for over $1.7 billion in milestone payments across multiple programs, plus tiered royalties on sales. This substantial investment shows the partners’ belief in Isomorphic Labs’ ability to deliver far-reaching AI solutions for drug discovery. These partnerships aim to combine Isomorphic’s AI-driven target identification and molecule generation capabilities with the pharmaceutical companies’ deep biological and clinical expertise. The structural terms emphasize a collaborative research framework where Isomorphic Labs applies its foundation models to its partners’ therapeutic areas of interest, with success-based remuneration incentivizing the delivery of viable drug candidates. This model allows pharmaceutical companies to access state-of-the-art AI without the need to build an equivalent internal AI foundation model development team from scratch, while providing Isomorphic Labs with critical biological data and validation pathways. Isomorphic Labs-Amgen partnership details
The Role of Foundation Models vs. Point Solutions
The common thread running through these high-profile collaborations is the emphasis on foundation models rather than narrow point algorithms. Foundation models, characterized by their vast scale, generalizability, and ability to learn from diverse datasets, offer a distinct advantage in drug discovery. Unlike point solutions designed for a single task (e.g., predicting solubility for a specific class of molecules), foundation models can be fine-tuned for a multitude of tasks across the entire drug discovery continuum. For biotech investors and pharmaceutical business development executives, this distinction is critical. Investing in or partnering with developers of scalable foundation models, such as those from NVIDIA or Isomorphic Labs, offers a higher return on investment due to their broad applicability and potential for continuous improvement. These models are designed to learn and adapt, making them resilient to algorithmic drift and capable of handling novel biological challenges. Companies like Schrodinger, while offering powerful computational chemistry platforms, often represent a more specialized toolset compared to the ambition of a truly generalized foundation model for de novo drug design. The strategic imperative is to seek out AI partners whose capabilities are built on these broad, adaptable platforms, rather than those offering highly specialized, potentially siloed algorithms. Overview of foundation models in drug discovery
Audience Takeaway: Prioritizing Scalable Foundation Models
For investors and executives working through the increasingly competitive healthcare AI competitive field 2026, the key takeaway is clear: prioritize AI partners with scalable foundation models over narrow point algorithms. The future of drug discovery lies in AI systems capable of learning across vast and varied biological data, generating novel hypotheses, and accelerating experimental validation. These foundational AI capabilities, when integrated strategically through partnerships, offer the most direct path toward overcoming the long-standing challenges of drug development. The structural terms of the Genentech-NVIDIA and Isomorphic-Eli Lilly and Novartis deals exemplify this approach, demonstrating a clear preference for deep, long-term collaborations that embed modern AI at the core of pharmaceutical innovation. This analysis is grounded in publicly disclosed partnership terms and corporate press announcements, reflecting the strategic decisions being made at the highest levels of the pharmaceutical and AI industries.
Frequently Asked Questions
Why are pharmaceutical companies outsourcing foundational AI development instead of building it internally?
Pharmaceutical companies are outsourcing foundational AI development because the complexity and computational demands of creating cutting-edge AI foundation models often exceed their core competencies and infrastructure. This strategy allows them to leverage specialized expertise in machine learning, high-performance computing, and vast data handling from AI-native companies and technology leaders. These partnerships embed advanced AI capabilities directly into the drug discovery pipeline, aiming to build scalable, generalizable AI frameworks.
What kind of financial and structural terms characterize these external AI partnerships in drug discovery?
These partnerships typically involve significant investment from the pharmaceutical partner, including access to proprietary biological data and domain expertise, in exchange for cutting-edge AI capabilities and computational resources. Structural terms often include multi-year agreements, joint development teams, and performance-based milestones tied to the successful application of AI in specific drug discovery programs. For example, the Isomorphic Labs deal with Eli Lilly included an upfront payment of $45 million, with potential for over $1.7 billion in milestone payments.
What is the key advantage of foundation models over point solutions in drug discovery AI partnerships?
The key advantage of foundation models is their vast scale, generalizability, and ability to learn from diverse datasets, offering a distinct advantage in drug discovery. Unlike narrow point solutions designed for a single task, foundation models can be fine-tuned for a multitude of tasks across the entire drug discovery continuum. This broad applicability and potential for continuous improvement offer a higher return on investment for partners.
